EN PL

News

FDA: Guidance for industry: Immunogenicity Assessment for Therapeutic Protein Product

21.08.2014
This guidance is intended to assist manufacturers and clinical investigators involved in the development of therapeutic protein products for human use. In this document, FDA outlines and ...

RAPS: Are New Policies Needed to Help Regulate Generic Drugs? FDA Wants to Know

21.08.2014
US drug regulators are getting ready to take a close look at the regulation of generic drugs, including new policies recently proposed by the US Food and Drug Administration (FDA) and areas that ...

EMA: Checking process of mock-ups and specimens of outer / immediate labelling and package leaflets of human medicinal products in the centralised procedure

14.08.2014
Since February 2007 the European Medicines Agency (EMA) has been operating an extensive checking process of the marketing-authorisation holder’s (MAH) printed packaging materials for outer and ...

FDA: Upper Facial Lines: Developing Botulinum Toxin Drug Products

14.08.2014
The purpose of this guidance is to assist sponsors in the clinical development of therapeutic biological products, specifically botulinum toxins, for the temporary improvement in the appearance of ...

EMA: EMA publishes Document on the Validation of analytical Methods

14.08.2014
The European Medicines Agency (EMA) published the concept paper \"Transferring quality control methods validated in collaborative trials to a product/laboratory specific context\". To accept a ...

GMP: Serious GMP Violations found at Chinese API Manufacturer - Basic GMP principles not followed

14.08.2014
On 7 July 2014 the US FDA has issued a Warning Letter for Zhejiang Jiuzhou Pharmaceutical Co., Ltd. located in Taizhou, Zhejiang Province in China. The company is a producer of APIs and failed to ...

RAPS: FDA Revises Labeling Guidance to Clarify Clinical Pharmacology Recommendation

14.08.2014
A new draft guidance document published by the US Food and Drug Administration (FDA) seeks to help sponsors with the \"clinical pharmacology\" sections that accompany an approved drug\'s labeling. ...

EMA: Draft reflection paper on classification of advanced-therapy medicinal products

07.08.2014
This reflection paper has been updated to reflect the current thinking of the Committee on Advanced Therapies (CAT) on substantial manipulation and non-homologous use. Additional changes have been ...

EMA: Draft reflection paper on the use of cocrystals and other solid-state forms of active substances in medicinal products

07.08.2014
The content of this reflection paper represents the current thinking of the Committee for Medicinal Products for Human Use / Committee for Medicinal Products for Veterinary Use Quality Working ...

EMA: Draft reflection paper on the use of patient reported outcome (PRO) measures in oncology studies

07.08.2014
The importance of the patient’s point of view on their health status is fully acknowledged and such information may in principle be used in drawing regulatory conclusions regarding treatment ...